For example, targeting ALK has shown success in treatments of ALK(+) non-small cell lung cancers and also in childhood anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor using the ALK inhibitor crizotinib [92]. Here, ALK is linked to anaplastic large cell lymphoma.